Antisense oligonucleotide mediated exon skipping therapy development for Duchenne muscular dystrophy takes more than an oligonucleotide

29 March 2022

Click to watch this webinar

‘Antisense oligonucleotide mediated exon skipping therapy development for Duchenne muscular dystrophy takes more than an oligonucleotide’​ by Annemieke Aartsma-Rus

29 March 2022, 3-4pm CEST

The speaker is Professor of Translational Genetics at the Department of Human Genetics at the Leiden University Medical Center, the Netherlands. She is also Co-founder and Co-leader of the Dutch Center for RNA Therapeutics (DCRT).

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission


“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern